Apply For FDI


Fraud Warning Disclaimer : FDI India warns you against certain individuals that might falsely present themselves as our affiliate agents, representatives, or employees. Under this false pretence, they might try to gain access to your personal information or to acquire money as Consultation fee or any other form or other valuables from you by offering fictitious employment opportunities or by claiming that they are contacting you on our behalf. Don’t fall prey into the fraudulent misrepresentation. Such fraudulent claims and offers are received generally via email, text message, phone, or internet, etc.

FDI India would like to bring to your notice that our authorized official Email IDs are,, and Contact Numbers are 1800 891 1610 and 8595911148. FDI India shall not be liable for any claims, damage, or loss of any kind inflicted by any other unauthorized entity. Be very mindful of such scams.
Legal : We own all the information, images, text, logo, and other content provided by us. The use of information is strictly prohibited without our consent. We hold the right to take a legal action against any individual or organization violating or using our site information.
Become A Partner Apply For FDI
Fdi India news

EAM Jaishankar and US Business Executives Talk About Investment and Job Creation

    29 May , 2021         Fdiindia

EAM Jaishankar and US Business Executives Talk About Investment and Job Creation

On Friday, US-India Strategic Partnership Forum Chief Mukesh Aghi said that External Affairs Minister S Jaishankar and US industry leaders discussed ways to boost investment, generate more employment, and transfer technology (local time). "During the COVID-19 controversy, US companies' commitment to India has grown significantly more robust. They employ their people, yet the contribution they contributed to India as a whole is worth noting, "He expressed himself.

Aghi went on to say that interest in investment and growth is still high, citing a 20 percent increase in FDI in India from US corporations over the previous year. Overall, the mood was positive, and they discussed ways to expand investment, generate more jobs, and transfer knowledge.

"Johnson and Johnson, under the QUAD partnership, has agreed to manufacture a billion doses of their vaccine in partnership with Bio E and to be distributed across the Indo Pacific region itself," he continued. "Whereas Moderna and Pfizer is a much more complex mRNA technology, which is difficult to transfer because you don't have the equipment, you don't have the trained manpower the manufacture."

When asked about the pharma businesses and business leaders who attended the meeting, Aghi noted that there were pharma businesses like Abbott and Merck and a wide array of corporations, geopolitical leaders, and strategic thinkers. It was a closed-door meeting, but the mood was upbeat, and there was a lot of support for India.

He highlighted the COVID-19 issues, saying that businesses in India and the United States are struggling to get back to business as usual, get their production up and running, or relocate their services from India to the rest of the world.

He explained that Atmanirbhar Bharat had not been miscalculated "India supplies 40% of generic pharmaceuticals to the United States, but it imports 70% of API from China. There's an element of danger there. Then there were difficulties when we first began supplying concentrated oxygen to India."

He also added, "All vaccines are shipped under the Indian Red Cross, Indian Red Cross brand. They disperse it to several states. Then we'll bring in Deloitte, who will be our audit partner on this. They provide us with input on how things are progressing and how they are being dispersed, resulting in a transparent approach."

"One of the messages we sent to the Indian government was that India and China are on par when it comes to labor expenses, taxes, and electricity expenses. However, because logistics costs are higher in India, manufacturing costs are 20% higher. "He went on to say